









Markets
/
Stocks
/
nasdaq-shph
/

Shuttle Pharmaceuticals Holdings Inc

SHPH

1.630USD

+0.060+3.82%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.01MMarket Cap

LossP/E TTM



Shuttle Pharmaceuticals Holdings Inc

1.630

+0.060+3.82%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Shuttle Pharmaceuticals Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Shuttle Pharmaceuticals Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 214 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Shuttle Pharmaceuticals Holdings Inc's Score

Industry at a Glance

Industry Ranking

214 / 392

Overall Ranking

436 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Shuttle Pharmaceuticals Holdings Inc Highlights

StrengthsRisks

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -2.30, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 170.29K shares, increasing 48.48% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.98.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Shuttle Pharmaceuticals Holdings Inc is 7.00, ranking 169 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.00

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Shuttle Pharmaceuticals Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Shuttle Pharmaceuticals Holdings Inc is 6.66, ranking 241 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.30, which is -99.91% below the recent high of -0.00 and -53.38% above the recent low of -3.53.

Score

Industry at a Glance

Previous score

6.66

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 214/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Shuttle Pharmaceuticals Holdings Inc. The Biotechnology & Medical Research industry's average is 8.05.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Shuttle Pharmaceuticals Holdings Inc is 6.42, ranking 251 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.62 and the support level at 0.47, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.40

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.112

Neutral

RSI(14)

43.368

Neutral

STOCH(KDJ)(9,3,3)

8.385

Oversold

ATR(14)

0.481

Low Volatility

CCI(14)

-120.303

Sell

Williams %R

95.904

Oversold

TRIX(12,20)

0.233

Sell

StochRSI(14)

30.475

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.688

Sell

MA10

1.908

Sell

MA20

1.877

Sell

MA50

1.782

Sell

MA100

2.560

Sell

MA200

3.453

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Shuttle Pharmaceuticals Holdings Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 6.35%, representing a quarter-over-quarter increase of 1412.29%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Connective Capital Management, LLC

100.53K

DRW Securities, LLC

42.83K

Dritschilo (Anatoly)

16.03K

Richards (Steven M)

8.40K

+93233.33%

Scorsis (George)

7.37K

Tung (Joseph)

7.37K

Nabyt (Oleh)

7.37K

Jung (Mira)

5.48K

+0.87%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Shuttle Pharmaceuticals Holdings Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.